-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Raises Price Target to $175

Benzinga·01/08/2026 12:16:56
Listen to the news
Morgan Stanley analyst Jeffrey Hung downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Equal-Weight and raises the price target from $173 to $175.